Adverse events for biologics in patients with CRSwNP: A meta‐analysis
Open Access
- 15 June 2022
- journal article
- letter
- Published by Wiley in Clinical and Translational Allergy
- Vol. 12 (6) , e12169
Abstract
No abstract availableKeywords
All Related Versions
Funding Information
- National Natural Science Foundation of China (81970864)
This publication has 12 references indexed in Scilit:
- Efficacy and safety of omalizumab in nasal polyposis: 2 randomized phase 3 trialsJournal of Allergy and Clinical Immunology, 2020
- Efficacy and safety of treatment with biologicals (benralizumab, dupilumab, mepolizumab, omalizumab and reslizumab) for severe eosinophilic asthma. A systematic review for the EAACI Guidelines ‐ recommendations on the use of biologicals in severe asthmaAllergy, 2020
- Efficacy and safety of dupilumab in patients with severe chronic rhinosinusitis with nasal polyps (LIBERTY NP SINUS-24 and LIBERTY NP SINUS-52): results from two multicentre, randomised, double-blind, placebo-controlled, parallel-group phase 3 trialsThe Lancet, 2019
- Dermatomyositis associated with omalizumab therapy for severe asthma: a case reportAllergy, Asthma & Clinical Immunology, 2019
- Reduced need for surgery in severe nasal polyposis with mepolizumab: Randomized trialJournal of Allergy and Clinical Immunology, 2017
- Inflammatory endotypes of chronic rhinosinusitis based on cluster analysis of biomarkersJournal of Allergy and Clinical Immunology, 2016
- Effect of Subcutaneous Dupilumab on Nasal Polyp Burden in Patients With Chronic Sinusitis and Nasal PolyposisJAMA, 2016
- Omalizumab is effective in allergic and nonallergic patients with nasal polyps and asthmaJournal of Allergy and Clinical Immunology, 2013
- Mepolizumab, a humanized anti–IL-5 mAb, as a treatment option for severe nasal polyposisJournal of Allergy and Clinical Immunology, 2011
- A Study to Evaluate Safety and Efficacy of Mepolizumab in Patients with Moderate Persistent AsthmaAmerican Journal of Respiratory and Critical Care Medicine, 2007